EUVIMEDEUVIMED entdecken
Crossref

Implementing a Program of Comprehensive Tuberculosis Preventive Treatment: Safety, Effectiveness, and Acceptability of Moxifloxacin or Bedaquiline Use for Contacts Exposed to Drug-Resistant Strains

Alexandra V Solovyeva iD, Grigory V Volchenkov iD, Oksana I Ponomarenko, Tatiana A Kuznezova, Tatiana R Somova, Evgenia V Belova, Sven Gudmund Hinderaker iD, Einar Heldal iD, Salmaan Keshavjee iD

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciaf701 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Alexandra V Solovyeva und 8 weiteren Autor:innen. Beteiligte Einrichtung: Independent Nonprofit Organization Center of Partnership Assistance in Healthcare "Zdorovye.ru", Moscow, Russia. Hauptthemen laut MEDLINE: Moxifloxacin, Diarylquinolines, Antitubercular Agents, Tuberculosis, Multidrug-Resistant. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Vladimir, Eli Lilly and Company Foundation, Brigham and Women's Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rates of drug-resistant tuberculosis (DR-TB) are increasing worldwide. Tuberculosis preventive treatment (TPT) for contacts of people with active TB is essential to halt infection progression and transmission. While newer TPT regimens for exposure to drug-susceptible and rifampin (R)-resistant strains (MDR-TB/RR-TB) are expanding, optimal treatment for contacts exposed to fluoroquinolone-resistant strains of TB (pre-XDR- or XDR-TB) remains unclear. In 2019–2020, Vladimir City, Russia, introduced moxifloxacin (Mfx)- and bedaquiline (Bdq)-based TPT regimens to prevent disease development in contacts exposed to MDR/RR-TB and pre-XDR-TB.

Methods

We conducted a retrospective cohort study of adult TB contacts, people experiencing homelessness, and people with HIV who received TPT in Vladimir between 2019 and 2020. Those without TB disease but with indications for TPT were offered 1 of 6 regimens, based on drug-susceptibility testing results of the index patient: rifapentine/isoniazid (3HP), isoniazid (6H), rifabutin/isoniazid (3HRb), 4R, 4Mfx, or 3Bdq. Adverse drug reactions (ADRs) were monitored with monthly lab tests and electrocardiogram (ECGs). Outcome measures included ADRs, TPT completion, and TB disease incidence during the 12-month follow-up period.

Results

Over 24 months, 403 people started TPT. No life-threatening ADRs or deaths occurred. The lowest ADR rate and highest completion were seen with 3Bdq (95.2%) compared to 3HP (75.9%, Mid-P exact = .03). Tuberculosis incidence per 1000 person-years was 4 times higher among eligible individuals who declined TPT versus those initiating it.

Conclusions

Preventive therapy for drug-resistant TB, including fluoroquinolone-resistant strains, is acceptable, safe, and effective. Implementation of comprehensive TPT programs in high-burden DR-TB settings can protect contacts and reduce transmission.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MoxifloxacinDiarylquinolinesAntitubercular AgentsTuberculosis, Multidrug-ResistantHumansRetrospective StudiesFemaleAdultMaleRussiaMiddle AgedMycobacterium tuberculosis

Stichwörter der Autor:innen

DR TPT (drug-resistant TB preventive treatment)bedaquilinedrug-resistant tuberculosis infectionmoxifloxacinpreventive therapy

Substanzen

MoxifloxacinDiarylquinolinesbedaquilineAntitubercular Agents

Autor:innen und Institutionen

  • Independent Nonprofit Organization Center of Partnership Assistance in Healthcare "Zdorovye.ru", Moscow, Russia.
  • Vladimir Regional TB Control Center, Vladimir, Russia.
  • Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
  • LHL International, Oslo, Norway.
  • Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, USA.
  • Division of Global Health Equity, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.

ORCID-Profile: Alexandra V Solovyeva, Grigory V Volchenkov, Sven Gudmund Hinderaker, Einar Heldal, Salmaan Keshavjee

Förderung

  • Vladimir
  • Eli Lilly and Company Foundation
  • Brigham and Women's Hospital
  • Partners in Health
  • SORT IT
  • LHL International

Zitieren

APA

Solovyeva, A. V., Volchenkov, G. V., Ponomarenko, O. I., Kuznezova, T. A., Somova, T. R., Belova, E. V., Hinderaker, S. G., Heldal, E., & Keshavjee, S. (2026). Implementing a Program of Comprehensive Tuberculosis Preventive Treatment: Safety, Effectiveness, and Acceptability of Moxifloxacin or Bedaquiline Use for Contacts Exposed to Drug-Resistant Strains. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf701

Vancouver

Solovyeva AV, Volchenkov GV, Ponomarenko OI, Kuznezova TA, Somova TR, Belova EV, et al. Implementing a Program of Comprehensive Tuberculosis Preventive Treatment: Safety, Effectiveness, and Acceptability of Moxifloxacin or Bedaquiline Use for Contacts Exposed to Drug-Resistant Strains. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf701

BibTeX
@article{Solovyeva2026,
  author = {Solovyeva, Alexandra V and Volchenkov, Grigory V and Ponomarenko, Oksana I and Kuznezova, Tatiana A and Somova, Tatiana R and Belova, Evgenia V and Hinderaker, Sven Gudmund and Heldal, Einar and Keshavjee, Salmaan},
  title = {Implementing a Program of Comprehensive Tuberculosis Preventive Treatment: Safety, Effectiveness, and Acceptability of Moxifloxacin or Bedaquiline Use for Contacts Exposed to Drug-Resistant Strains},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciaf701}
}
Kostenlos starten →